NVX-CoV2373

COVID-19 vaccine, recombinant, matrix-M adjuvanted · Novavax

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for NVX-CoV2373, covering 2021-02-03 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults [Phase 3]